March 9, 2020 06:50 AM EDTUpdated 06:40 PM
Financing

Tri­fec­ta of clin­i­cal stage biotechs un­veil IPO plans, brav­ing Wall Street's coro­n­avirus pan­ic

Natalie Grover

Reporter

Coro­n­avirus fears pre­cip­i­tat­ed a rout on glob­al stock prices on Mon­day, but three clin­i­cal-stage biotechs are sol­dier­ing on with plans …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times